Skip to content

Dietary Treatments for Cognitive Impairment in Older Adults

Feasibility and Efficacy of Dietary Interventions for Cognitive Impairment in Older Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02521818
Enrollment
38
Registered
2015-08-13
Start date
2015-08-31
Completion date
2019-07-01
Last updated
2019-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment, Probable Alzheimer's Disease

Keywords

cognition, dementia, neuropsychological, elderly, nutrition, diet

Brief summary

This trial seeks to establish the feasibility of implementing a ketogenic, modified Atkins diet (MAD) to older adults with mild cognitive impairment (MCI) or early Alzheimer's disease (AD) living in the community. A secondary aim is to determine whether adherence to the MAD results in better cognitive test scores than adherence to a non-ketogenic control diet. A final aim is to determine the role of apolipoprotein E (ApoE) genotype in participants' response to the MAD. Participants will be randomly assigned to a 12-week trial of either the MAD or a placebo diet based on the National Institute on Aging's recommendations for senior nutrition.

Detailed description

It is well established that Alzheimer's disease (AD) is associated with insulin resistance and, hence, abnormal glucose metabolism. In fact, abnormalities in the brain's uptake of glucose can be observed on PET imaging in advance of clinical symptoms. In patients with established dementia due to AD, the severity of cognitive impairment is strongly correlated with the decrease in glucose uptake. Ketone bodies, the products of fat metabolism, can serve as a backup fuel when glucose is unavailable. Ketone body metabolism appears to bypass the metabolic processes that are abnormal in AD and may provide better nourishment for neurons. As a result, ketone body metabolism may slow cognitive decline or even improve cognition in patients with AD. Participants will be 60 people, age 60 or older, with MCI or mild probable AD and without significant cardiovascular disease. They will be required to obtain the consent of their primary care physicians for their participation. Each patient will have a study partner who is cognitively healthy, lives with the participant, and can help him/her adhere to the diet. A research dietitian will teach participants and partners the new diet and monitor participants' adherence with food logs, in-person assessments, and urine ketone testing. After an initial baseline visit, participants will complete four in-person assessments during which adherence to the diet will be assessed and neurocognitive tests will be administered. It is hypothesized that the MAD will be feasible and well tolerated by seniors with MCI and AD. It is further hypothesized that adherence to the MAD will be associated with a greater increase (or less decline) in cognitive test scores than the placebo diet, particularly for those participants who do not carry an ApoE ε4 allele.

Interventions

OTHERModified Atkins Diet
OTHERNIA Diet for Seniors

Sponsors

Johns Hopkins University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* diagnosis of mild cognitive impairment or Alzheimer's disease * availability of cohabitating study partner without cognitive impairment * consent of primary care physician

Exclusion criteria

* history of stroke * history of coronary artery disease * history of pancreatitis * untreated hypothyroidism or B12 deficiency * history of renal disease or recurrent kidney stones * history of liver disease * insulin-dependent diabetes * body mass index \<18.5 * multiple food allergies * follow strict diet (e.g., vegetarian, gluten-free)

Design outcomes

Primary

MeasureTime frameDescription
Feasibility for MAD Group12 weeksAchieving moderate ketosis (\>=40 mg.dl) at 3 consecutive follow-up visits
Feasibility for Control Group12 weeksAchieving a Healthy Eating Index (\>=85) at 3 consecutive follow-up visits

Secondary

MeasureTime frameDescription
Efficacy for Cognition12 weeksComposite Memory Score (mean z-score on delayed recall of HVLT-R and BVMT-R)
Efficacy for Function12 weeksChange in MDS-HC Instrumental Activities of Daily Living Score

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026